NCT03491553 - Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 6, 2018

Primary Completion Date

March 22, 2019

Study Completion Date

August 10, 2020

Conditions

Chronic Hepatitis B

Interventions

DRUG

Selgantolimod

Tablet(s) administered orally once weekly

DRUG

Placebo

Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly

DRUG

Hepatitis B virus (HBV) OAV Therapy

"Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)"

Trial Locations (2)

1010

Auckland Clinical Studies Limited, Auckland

21201

University of Maryland, Institute of Human Virology, Baltimore